Le Lézard
Classified in: Health, Business
Subject: CON

World-leading Hospital Mayo Clinic Orders SyntheticMR's Solution For Clinical Routine

STOCKHOLM, March 27, 2020 /PRNewswire/ -- SyntheticMR announced today that they have received a purchase order from Mayo Clinic for its medical imaging software solution SyMRI.

Mayo Clinic is ranked the No. 1 hospital in the US and receives more than 1.2 million patients from all 50 states. The purchase order relates to SyntheticMR's product SyMRI for use in clinical routine, which will support shorter scan times while providing more information to the clinician.

"I see great potential in quantitative MRI and SyMRI as a product," says Dr Wende Gibbs, Neuroradiologist at Mayo Clinic. "The ability to add multi-parametric maps and myelin into our clinical routine will be a great benefit to our patients." 

"I am excited to work with the clinicians at Mayo Clinic to bring the benefits of quantitative MRI to patients across their institutions," says Kyle Frye, President SyntheticMR US Inc. "Our technology can speed up their imaging workflow while helping their radiologists and referring clinicians make the best possible diagnosis and treatment follow up."

The product will be installed across all three Mayo Clinic campuses; Rochester in Minnesota, Phoenix/Scottsdale in Arizona and Jacksonville in Florida. SyMRI will be utilized in combination with all three major vendors, GE, Siemens and Philips as a fully vendor agnostic solution.

"I look forward to working with Mayo Clinic to bring quantitative MRI into their clinical practice," says Ulrik Harrysson, CEO SyntheticMR. "The fact that such an important hospital group like Mayo Clinic is ready to invest in our product is a testament to its potential."

For additional information, please contact 
Ulrik Harrysson, CEO,
SyntheticMR AB, +46-70-529-29-87 

Kyle Frye at
+1(859)512-9496 or 

This information was brought to you by Cision http://news.cision.com


The following files are available for download:







These press releases may also interest you

at 11:23
Today, Samaritan's Purse deployed its Emergency Field Hospital to New York City, New York, where the local medical infrastructure is severely overwhelmed. In cooperation with the Federal Emergency Management Agency (FEMA), New York state officials,...

at 11:01
Novartis today announced results from a prespecified analysis of pooled data from three Phase III studies evaluating the safety and efficacy of inclisiran, its first-in-class investigational treatment for hyperlipidemia in adults. The data was...

at 11:00
As the impact of the Coronavirus (COVID-19) is now felt worldwide, we want to assure our customers and partners that we are still here to support you. Zenner's operations remain open with regular operating hours. Zenner's number one priority is...

at 10:13
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg...

at 10:05
Merck , known as MSD outside the United States and Canada, today announced the presentation of results from the VICTORIA trial, a Phase 3 study evaluating the efficacy and safety of its investigational drug vericiguat, an orally administered soluble...

at 10:00
Amgen today announced positive results from the EvolocumaB Effect on LDL-C LowerIng in SubJEcts with Human Immunodeficiency ViRus and INcreased Cardiovascular RisK (BEIJERINCK) study evaluating the efficacy and safety of Repatha® (evolocumab) in...

News published on 27 march 2020 at 04:08 and distributed by: